- Home
- FRME vs AMRX Comparison
FRME vs AMRX Comparison
Compare FRME & AMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FRME
- AMRX
- Stock Information
- Founded
- FRME 1893
- AMRX 2002
- Country
- FRME United States
- AMRX United States
- Employees
- FRME N/A
- AMRX N/A
- Industry
- FRME Major Banks
- AMRX Biotechnology: Pharmaceutical Preparations
- Sector
- FRME Finance
- AMRX Health Care
- Exchange
- FRME Nasdaq
- AMRX Nasdaq
- Market Cap
- FRME 2.1B
- AMRX 2.3B
- IPO Year
- FRME N/A
- AMRX N/A
- Fundamental
- Price
- FRME $35.93
- AMRX $7.82
- Analyst Decision
- FRME Buy
- AMRX Strong Buy
- Analyst Count
- FRME 4
- AMRX 4
- Target Price
- FRME $45.50
- AMRX $11.50
- AVG Volume (30 Days)
- FRME 244.6K
- AMRX 1.6M
- Earning Date
- FRME 07-24-2025
- AMRX 08-08-2025
- Dividend Yield
- FRME 4.02%
- AMRX N/A
- EPS Growth
- FRME 2.61
- AMRX N/A
- EPS
- FRME 3.55
- AMRX N/A
- Revenue
- FRME $615,411,000.00
- AMRX $2,830,186,000.00
- Revenue This Year
- FRME $15.14
- AMRX $9.84
- Revenue Next Year
- FRME $5.03
- AMRX $7.33
- P/E Ratio
- FRME $10.10
- AMRX N/A
- Revenue Growth
- FRME N/A
- AMRX 13.42
- 52 Week Low
- FRME $31.16
- AMRX $6.29
- 52 Week High
- FRME $46.13
- AMRX $9.48
- Technical
- Relative Strength Index (RSI)
- FRME 41.12
- AMRX 54.91
- Support Level
- FRME $35.11
- AMRX $7.72
- Resistance Level
- FRME $38.19
- AMRX $8.11
- Average True Range (ATR)
- FRME 0.88
- AMRX 0.26
- MACD
- FRME -0.19
- AMRX 0.05
- Stochastic Oscillator
- FRME 23.10
- AMRX 72.12
About FRME First Merchants Corporation
First Merchants Corp, through its subsidiaries, provides its customers with financial services delivered locally by bankers. It offers personal banking, business banking, real estate mortgage lending, cash management services, brokerage, wealth management, and insurance. The company reports in only one segment which is community banking.
About AMRX Amneal Pharmaceuticals Inc.
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE - It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.